Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hi-Tech acquires Midlothian’s assets

This article was originally published in The Tan Sheet

Executive Summary

Amityville, N.Y.-based Hi-Tech Pharmacal signed an agreement Dec. 31 to acquire the assets of Midlothian Laboratories for $5 million, the firm says. Additionally, Hi-Tech will pay almost $1 million for inventory and potentially up to $1 million in performance incentives tied to future Midlothian product sales and abbreviated new drug application approval. Hi-Tech will receive rights to Midlothian's portfolio of prescription nutritional supplements as well as future ANDA and non-ANDA products in development. According to Hi-Tech, Midlothian had sales of approximately $5.6 million and pre-tax income of $800,000 in 2006...

You may also be interested in...



Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

AstraZeneca Vaccine May Only Gain EU Approval In Under 70s

AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.

Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug

The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel